Contact Us
Drug Search Results
More Filters [+]

Rolapitant

Alternative Names: rolapitant, sch 619734, varubi
Latest Update: 2023-09-26
Latest Update Note: News Article

Product Description

Rolapitant is a highly selective neurokinin-1 (NK-1) receptor antagonist with very good oral activity, central nervous system penetration and a long (180-hour) plasma half-life.  (Sourced from: https://pubmed.ncbi.nlm.nih.gov/28393710/)

Mechanisms of Action: NK1 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Belgium | European Medicines Agency | France | Germany | Hungary | Ireland | Italy | Lithuania | Poland | Portugal | Spain | Sweden | United Kingdom | United States

Approved Indications: Oncology Unspecified

Known Adverse Events: Dizziness | Neutropenia | Hiccup

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Rolapitant

Countries in Clinic: China

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
CTR20212383

P1

Not yet recruiting

Healthy Volunteers

None

Recent News Events

Date

Type

Title

09/26/2023

News Article

 Chemotherapy-Induced Nausea and Vomiting Drugs Market, Global Outlook and Forecast 2023-2032

03/09/2023

News Article

 ROME Therapeutics Appoints Keith Wilcoxen, Ph.D., as Executive Vice President, Early Development

03/06/2023

News Article

 DiaMedica Therapeutics Announces the Appointment of Biopharma Veteran Tanya Lewis to Its Board of Directors

10/01/2021

News Article

 Cybin Announces Appointment of Dr. Amir Inamdar as Chief Medical Officer for European Operations and Dr. Geoff Varty as the Head of Research and Development

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions